The presence of the short (GT)n allelic variant of the HMOX1 promoter correlates with a higher risk and worse prognosis for ALL patients, and is associated with a higher rate of CIN incidents. This evidence concerns the gene HMOX1 and acute lymphoblastic leukemia.